AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38805527 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of dorsal nerve roots via epidural lead placement
Number of subjects: 16
Study 38805536 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam sedation
Number of subjects: 0
Study 38805536 — intervention group
Group type: COMPARATOR
Intervention: No sedation (control group)
Number of subjects: 0
Study 38805559 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochromatographic-test (ICT)
Number of subjects: 58
Study 38805668 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIDE
Number of subjects: 1171
Study 38805668 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 1171
Study 38805668 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 1171
Study 38805733 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level light therapy (LLLT)
Number of subjects: 0
Study 38805733 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (placebo)
Number of subjects: 0
Study 38805784 — intervention group
Group type: EXPERIMENTAL
Intervention: WM training (12 half-hour sessions)
Number of subjects: 30
Study 38805853 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted cHA-based IIV
Number of subjects: 0
Study 38805853 — intervention group
Group type: EXPERIMENTAL
Intervention: LAIV
Number of subjects: 0
Study 38805853 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjuvanted cHA-based IIV
Number of subjects: 0
Study 38805853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38806045 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine TAK-003 (high-dose formulation)
Number of subjects: 0
Study 38806045 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine TAK-003 (standard approved formulation)
Number of subjects: 0
Study 38806045 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38806190 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg once daily
Number of subjects: 0
Study 38806190 — intervention group
Group type: COMPARATOR
Intervention: adalimumab 40 mg every other week
Number of subjects: 0
Study 38806190 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib
Number of subjects: 0
Study 38806195 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus chemotherapy
Number of subjects: 997
Study 38806195 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 997
Study 38806315 — intervention group
Group type: EXPERIMENTAL
Intervention: IDRA tool risk assessment
Number of subjects: 145
Study 38806315 — intervention group
Group type: EXPERIMENTAL
Intervention: IDRA tool
Number of subjects: 145
Study 38806421 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent care pathway
Number of subjects: 0
Study 38806430 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopic thermal vapour ablation (BTVA) treatment with the InterVapor system together with standard medical management
Number of subjects: 224
Study 38806430 — intervention group
Group type: COMPARATOR
Intervention: Standard medical management alone (according to GOLD guidelines)
Number of subjects: 224
Study 38806430 — intervention group
Group type: EXPERIMENTAL
Intervention: BTVA treatment
Number of subjects: 224
Study 38806430 — intervention group
Group type: COMPARATOR
Intervention: Standard medical management alone
Number of subjects: 224
Study 38806467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting and protein pacing (IF-P)
Number of subjects: 41
Study 38806467 — intervention group
Group type: COMPARATOR
Intervention: Calorie-restricted (CR) diet
Number of subjects: 41
Study 38806504 — intervention group
Group type: EXPERIMENTAL
Intervention: NOX-A12 (200/400/600 mg per week)
Number of subjects: 10
Study 38806504 — intervention group
Group type: EXPERIMENTAL
Intervention: NOX-A12 (600 mg per week)
Number of subjects: 10
Study 38806504 — intervention group
Group type: EXPERIMENTAL
Intervention: NOX-A12 (various doses)
Number of subjects: 10
Study 38806700 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1467335 10 mg once daily for 12 weeks
Number of subjects: 79
Study 38806700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 38806873 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam injection via needle-free auto-injector ZENEO (10 mg)
Number of subjects: 40
Study 38806873 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe midazolam injection (10 mg)
Number of subjects: 40
Study 38807042 — intervention group
Group type: EXPERIMENTAL
Intervention: Video streaming used during the call
Number of subjects: 113
Study 38807042 — intervention group
Group type: COMPARATOR
Intervention: No video streaming used during the call
Number of subjects: 113
Study 38807063 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Problem Solving (SPS) intervention
Number of subjects: 0
Study 38807063 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 38807091 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led community-based intervention providing sexual and reproductive health (SRH) services with a prevention points card (PPC) system.
Number of subjects: 20
Study 38807091 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention).
Number of subjects: 20
Study 38807116 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-based simulation training on geriatric oral health care (implemented twice at two weeks apart)
Number of subjects: 50
Study 38807116 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training intervention)
Number of subjects: 50
Study 38807146 — intervention group
Group type: EXPERIMENTAL
Intervention: TG103 (15.0 mg)
Number of subjects: 48
Study 38807146 — intervention group
Group type: EXPERIMENTAL
Intervention: TG103 (22.5 mg)
Number of subjects: 48
Study 38807146 — intervention group
Group type: EXPERIMENTAL
Intervention: TG103 (30.0 mg)
Number of subjects: 48
Study 38807146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 38807160 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Number of subjects: 50
Study 38807160 — intervention group
Group type: COMPARATOR
Intervention: Pulpectomy
Number of subjects: 50
Study 38807165 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction-focused music therapy with cancer-affected children and their significant others (INMUT-KB)
Number of subjects: 52
Study 38807165 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy only with the child (MUT-K)
Number of subjects: 52
Study 38807165 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group (WLG)
Number of subjects: 52
Study 38807183 — intervention group
Group type: EXPERIMENTAL
Intervention: Social memory task administered in presence-only context
Number of subjects: 92
Study 38807183 — intervention group
Group type: EXPERIMENTAL
Intervention: Social memory task administered in observation context
Number of subjects: 92
Study 38807183 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment measuring social interactions and abilities
Number of subjects: 92
Study 38807183 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple comparative case study
Number of subjects: 92
Study 38807515 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 U RTU abobotulinumtoxinA
Number of subjects: 150
Study 38807515 — intervention group
Group type: COMPARATOR
Intervention: 20 U powder BoNT-A
Number of subjects: 150
Study 38807643 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD-DS
Number of subjects: 215
Study 38807643 — intervention group
Group type: COMPARATOR
Intervention: RYGB
Number of subjects: 215
Study 38807643 — intervention group
Group type: COMPARATOR
Intervention: SG
Number of subjects: 215
Study 38807685 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 114
Study 38807685 — intervention group
Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 114
Study 38807691 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Mindfulness-Based Program (MBP) for parents, 28 days duration, including 20 psychoeducation videos, homework audio guidance, and four instructor-led online group meetings
Number of subjects: 43
Study 38807691 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Mindfulness-Based Program (MBP) for parents
Number of subjects: 43
Study 38807691 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control Group
Number of subjects: 43
Study 38807948 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM) in addition to standard post-MI treatment
Number of subjects: 790
Study 38807948 — intervention group
Group type: COMPARATOR
Intervention: Standard post-MI treatment without ICM
Number of subjects: 790
Study 38807990 — intervention group
Group type: EXPERIMENTAL
Intervention: Live coaching with video-based exercise and mixed reality technology-driven exercise
Number of subjects: 128
Study 38807990 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 128
Study 38808136 — intervention group
Group type: EXPERIMENTAL
Intervention: AGT103-T treatment during ATI
Number of subjects: 6
Study 38808265 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking (NW) training group (n=14)
Number of subjects: 28
Study 38808265 — intervention group
Group type: COMPARATOR
Intervention: Free walking (FW) training group (n=14)
Number of subjects: 28
Study 38808319 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride 1000mg extended release once daily for 24 weeks in addition to standard-of-care WHO MB multidrug therapy (MDT) during 48 weeks.
Number of subjects: 166
Study 38808319 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks in addition to standard-of-care WHO MB multidrug therapy (MDT) during 48 weeks.
Number of subjects: 166
Study 38808361 — intervention group
Group type: EXPERIMENTAL
Intervention: SCG101 T-cell therapy
Number of subjects: 1
Study 38808476 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide (3 mg escalating to 14 mg)
Number of subjects: 32
Study 38808476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 38808490 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine (0.2 mg/kg infused intravenously over 40 minutes after childbirth)
Number of subjects: 364
Study 38808490 — intervention group
Group type: COMPARATOR
Intervention: Placebo (infused intravenously over 40 minutes after childbirth)
Number of subjects: 364
Study 38808490 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine
Number of subjects: 364
Study 38809014 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based telemonitoring group
Number of subjects: 94
Study 38809014 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 94
Study 38809014 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 94
Study 38809056 — intervention group
Group type: EXPERIMENTAL
Intervention: TREM-1 as a biomarker for diagnosis of kidney disease
Number of subjects: 0
Study 38809056 — intervention group
Group type: EXPERIMENTAL
Intervention: TREM-1 as a potential therapeutic target
Number of subjects: 0
Study 38809105 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based walking intervention for 3 months
Number of subjects: 366
Study 38809148 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated nnU-Net-based segmentation of abdominal organs using quantitative water-fat MRI
Number of subjects: 127
Study 38809174 — intervention group
Group type: EXPERIMENTAL
Intervention: Zodasiran 50 mg
Number of subjects: 204
Study 38809174 — intervention group
Group type: EXPERIMENTAL
Intervention: Zodasiran 100 mg
Number of subjects: 204
Study 38809174 — intervention group
Group type: EXPERIMENTAL
Intervention: Zodasiran 200 mg
Number of subjects: 204
Study 38809174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 38809322 — intervention group
Group type: EXPERIMENTAL
Intervention: MittEcho Measurement Feedback System (MFS)
Number of subjects: 701
Study 38809323 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (NO)
Number of subjects: 14
Study 38809537 — intervention group
Group type: EXPERIMENTAL
Intervention: Stomach-preserving surgery
Number of subjects: 451
Study 38809537 — intervention group
Group type: COMPARATOR
Intervention: Standard gastrectomy
Number of subjects: 451
Study 38809547 — intervention group
Group type: EXPERIMENTAL
Intervention: CLAD/LDAC/Ven
Number of subjects: 35
Study 38809547 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy
Number of subjects: 35
Study 38809554 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-to-consumer educational brochure (intervention group)
Number of subjects: 4225
Study 38809554 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 4225
Study 38809606 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-checker (SMASS) for self-triage
Number of subjects: 2543
Study 38809849 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfotiamine (600 mg or 1200 mg)
Number of subjects: 406
Study 38809849 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfotiamine (selected dose from phase 2A)
Number of subjects: 406
Study 38809849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 38809909 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Number of subjects: 153
Study 38809909 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 153
Study 38809948 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame-based motor-cognitive training with resonance breathing guided by heart-rate variability biofeedback (HRV-BF)
Number of subjects: 0
Study 38809948 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 38810010 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote self-measured blood pressure (SMBP) program with Bluetooth-enabled blood pressure cuff
Number of subjects: 119
Study 38810010 — intervention group
Group type: COMPARATOR
Intervention: Remote self-measured blood pressure (SMBP) program with manual entry
Number of subjects: 119
Study 38810010 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote SMBP program
Number of subjects: 119
Study 38810093 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg)
Number of subjects: 41
Study 38810093 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 41
Study 38810093 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study 38810172 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal antiseizure medication (ASM) exposure
Number of subjects: 324
Study 38810172 — intervention group
Group type: COMPARATOR
Intervention: Control group (children of healthy women)
Number of subjects: 324
Study 38810208 — intervention group
Group type: EXPERIMENTAL
Intervention: Open radical hysterectomy
Number of subjects: 0
Study 38810208 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive radical hysterectomy
Number of subjects: 0
Study 38810255 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-by-Step (SbS) digital mental health intervention
Number of subjects: 1249
Study 38810255 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 1249
Study 38810556 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on astragalus for 48 weeks
Number of subjects: 118
Study 38810556 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 118
Study 38810600 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (weekly induction of 600 mg or 900 mg followed by maintenance doses of 300 to 1200 mg every two weeks for up to 26 weeks)
Number of subjects: 11
Study 38810699 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC-2014
Number of subjects: 5036
Study 38810699 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC-2019
Number of subjects: 5036
Study 38810699 — intervention group
Group type: EXPERIMENTAL
Intervention: TELOS
Number of subjects: 5036
Study 38810699 — intervention group
Group type: EXPERIMENTAL
Intervention: PEITHO
Number of subjects: 5036
Study 38810699 — intervention group
Group type: EXPERIMENTAL
Intervention: Bova
Number of subjects: 5036
Study 38810699 — intervention group
Group type: EXPERIMENTAL
Intervention: NEWS2
Number of subjects: 5036
Study 38810699 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST
Number of subjects: 5036
Study 38810921 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized screening method
Number of subjects: 474
Study 38810921 — intervention group
Group type: COMPARATOR
Intervention: Traditional screening
Number of subjects: 474
Study 38810921 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized screening
Number of subjects: 474
Study 38810968 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified NHL-BFM-95 protocol combined with anaplastic lymphoma kinase inhibitor
Number of subjects: 136
Study 38810968 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified NHL-BFM-95 protocol combined with vinblastine (VBL)
Number of subjects: 136
Study 38810968 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaplastic lymphoma kinase inhibitor maintenance therapy
Number of subjects: 136
Study 38810968 — intervention group
Group type: COMPARATOR
Intervention: Low-risk group (R1)
Number of subjects: 136
Study 38810968 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-risk group (R2)
Number of subjects: 136
Study 38810968 — intervention group
Group type: COMPARATOR
Intervention: High-risk group (R3)
Number of subjects: 136
Study 38810968 — intervention group
Group type: COMPARATOR
Intervention: Patients with MDD (+)
Number of subjects: 136
Study 38810968 — intervention group
Group type: COMPARATOR
Intervention: Patients with stage IV cancer
Number of subjects: 136
Study 38810968 — intervention group
Group type: COMPARATOR
Intervention: Patients with SC/LH lymphoma
Number of subjects: 136
Study 38810968 — intervention group
Group type: COMPARATOR
Intervention: Patients with high-risk sites
Number of subjects: 136
Study 38811045 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil (iTRE) up to 12 breaths (72 µg) 4 times daily
Number of subjects: 76
Study 38811045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 38811104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI
Number of subjects: 1639
Study 38811104 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1639
Study 38811104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI (optimized)
Number of subjects: 1639
Study 38811104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI (unoptimized)
Number of subjects: 1639
Study 38811107 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 0 cardiac damage (women: 2.6%, men: 3.1%)
Number of subjects: 2026
Study 38811107 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 1 cardiac damage (women: 13.4%, men: 10.1%)
Number of subjects: 2026
Study 38811107 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 2 cardiac damage (women: 37.1%, men: 39.5%)
Number of subjects: 2026
Study 38811107 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 3 cardiac damage (women: 27.5%, men: 15.6%)
Number of subjects: 2026
Study 38811107 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 4 cardiac damage (women: 19.4%, men: 31.7%)
Number of subjects: 2026
Study 38811250 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematuria Cancer Risk Score (HCRS) with Renal Bladder Ultrasound (RBUS)
Number of subjects: 2484
Study 38811250 — intervention group
Group type: EXPERIMENTAL
Intervention: HCRS with RBUS
Number of subjects: 2484
Study 38811492 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 50-200 mg/day
Number of subjects: 0
Study 38811492 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV)
Number of subjects: 0
Study 38811502 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal self-dilation therapy (ESDT)
Number of subjects: 25
Study 38811502 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 38811502 — intervention group
Group type: EXPERIMENTAL
Intervention: ESDT
Number of subjects: 25
Study 38811554 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination bevacizumab (BVZ) therapy
Number of subjects: 74
Study 38811871 — intervention group
Group type: EXPERIMENTAL
Intervention: MAXPOWER Biological Antibacterial Liquid
Number of subjects: 100
Study 38811871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 38811888 — intervention group
Group type: EXPERIMENTAL
Intervention: IMT with 30% MIP
Number of subjects: 47
Study 38811888 — intervention group
Group type: EXPERIMENTAL
Intervention: IMT with 60% MIP
Number of subjects: 47
Study 38811888 — intervention group
Group type: COMPARATOR
Intervention: IMT with 10% MIP
Number of subjects: 47
Study 38811911 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) with 2.5 mg/ml ropivacaine
Number of subjects: 64
Study 38811911 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 64
Study 38811911 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 64
Study 38811947 — intervention group
Group type: EXPERIMENTAL
Intervention: Field-deployed ATSB stations
Number of subjects: 71
Study 38811947 — intervention group
Group type: COMPARATOR
Intervention: Non-deployed ATSB stations
Number of subjects: 71
Study 38811974 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 lockdowns
Number of subjects: 256
Study 38811974 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of overweight and obese children
Number of subjects: 256
Study 38811974 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of normal-weight children
Number of subjects: 256
Study 38811974 — intervention group
Group type: COMPARATOR
Intervention: Comparison to German reference population
Number of subjects: 256
Study 38811974 — intervention group
Group type: COMPARATOR
Intervention: U8 to U9 examinations
Number of subjects: 256
Study 38811985 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar spinal manipulation (SMT)
Number of subjects: 55
Study 38811985 — intervention group
Group type: COMPARATOR
Intervention: Deactivated ultrasound (control)
Number of subjects: 55